DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

The Latest 1-10

Study At ISPOR Europe Reveals Velphoro Could Be Cost-Effective; Can It Gain Ground on Renvela Across the Pond?

Category: DRG Blog

Approximately 75% of dialysis patients are on phosphate binders for the treatment of elevated serum phosphorus levels or hyperphosphatemia.1 The iron-...

Jihan Khan, Ph.D., Senior Business Insights Analyst  / 6 days ago
No comments
1-10 of 1379